Gilbert’s syndrome is the most common hereditary cause of elevated bilirubin levels and can be found in up to 5% of the population. This condition is characterized by an isolated increase in unconjugated bilirubin without any detectable liver disease. It is typically inherited in an autosomal recessive manner.

The elevated bilirubin levels in Gilbert’s syndrome do not have any serious consequences and tend to occur during times of stress, physical exertion, fasting, or infection. While it is often asymptomatic, some individuals may experience symptoms such as fatigue, decreased appetite, nausea, and abdominal pain.

The underlying cause of the increased bilirubin levels in this syndrome is a decrease in the activity of the enzyme glucuronyltransferase, which is responsible for conjugating bilirubin. In Gilbert’s syndrome, the bilirubin levels are generally less than three times the upper limit of normal, with more than 70% of the bilirubin being unconjugated. Liver function tests and LDH levels are typically within the normal range.

Oral rehydration therapy (ORT) is a method used to prevent or treat dehydration by replacing fluids in the body. It is a less invasive approach compared to other methods and has been successful in reducing the mortality rate of diarrhea in developing nations.

ORT includes glucose, such as 90 mmol/L in Dioralyte, which helps improve the absorption of sodium and water in the intestines and prevents low blood sugar levels. It also contains essential mineral salts.

According to current guidelines from the National Institute for Health and Care Excellence (NICE), for mild dehydration, it is recommended to administer 50 mL/kg of ORT over a period of 4 hours.

Once a child has been rehydrated, they should continue their normal daily fluid intake and consume an additional 200 ml of ORT after each loose stool. For infants, ORT should be given at 1-1.5 times their regular feeding volume, while adults should consume 200-400 mL of ORT after each loose stool.

For more information, you can refer to the NICE guidelines on the diagnosis and management of diarrhea and vomiting caused by gastroenteritis in children under 5 years old.

Primary sclerosing cholangitis (PSC) is a condition that affects the bile ducts, causing inflammation and blockage over time. It is more commonly seen in men than women, with a ratio of 3 to 1, and is typically diagnosed around the age of 40. PSC is characterized by recurring episodes of cholangitis and progressive scarring of the bile ducts. If left untreated, it can lead to liver cirrhosis, liver failure, and even hepatocellular carcinoma. PSC is often associated with ulcerative colitis, with more than 80% of PSC patients also having this condition. Other associations include fibrosis in the retroperitoneal and mediastinal areas.

When performing an endoscopic retrograde cholangiopancreatography (ERCP) to diagnose PSC, certain findings are typically observed. These include ulceration of the common bile duct, irregular narrowing with saccular dilatation above the structured ducts (resembling beads-on-a-string or a beaded appearance), and involvement of both the intra- and extrahepatic ducts simultaneously.

Complications that can arise from PSC include liver cirrhosis, portal hypertension, liver failure, and cholangiocarcinoma. Treatment options for PSC include the use of ursodeoxycholic acid to improve symptoms and liver function (although it does not affect the overall prognosis), cholestyramine to alleviate itching, and correction of deficiencies in fat-soluble vitamins. In some cases, endoscopic dilatation of strictures may be necessary.

Liver transplantation is the definitive treatment for PSC. The 10-year survival rate after transplantation is approximately 65%, and the average survival time from the time of diagnosis is around seven years. Patients with PSC often succumb to complications such as secondary biliary cirrhosis, portal hypertension, or cholangitis. Additionally, about 10% of PSC patients will develop cholangiocarcinoma.

Spontaneous bacterial peritonitis (SBP) is a condition that occurs as a complication of ascites, which is the accumulation of fluid in the abdomen. SBP typically presents with various symptoms such as fevers, chills, nausea, vomiting, abdominal pain, general malaise, altered mental status, and worsening ascites. This patient is at risk of developing alcoholic liver disease and cirrhosis due to their harmful levels of alcohol consumption. Harmful drinking is defined as drinking ≥ 35 units a week for women or drinking ≥ 50 units a week for men. The presence of shifting dullness and a distended abdomen are consistent with the presence of ascites. SBP is an acute bacterial infection of the ascitic fluid that occurs without an obvious identifiable cause. It is one of the most commonly encountered bacterial infections in patients with cirrhosis. Signs and symptoms of SBP include fevers, chills, nausea, vomiting, abdominal pain and tenderness, general malaise, altered mental status, and worsening ascites.

Further Reading:

Cirrhosis is a condition where the liver undergoes structural changes, resulting in dysfunction of its normal functions. It can be classified as either compensated or decompensated. Compensated cirrhosis refers to a stage where the liver can still function effectively with minimal symptoms, while decompensated cirrhosis is when the liver damage is severe and clinical complications are present.

Cirrhosis develops over a period of several years due to repeated insults to the liver. Risk factors for cirrhosis include alcohol misuse, hepatitis B and C infection, obesity, type 2 diabetes, autoimmune liver disease, genetic conditions, certain medications, and other rare conditions.

The prognosis of cirrhosis can be assessed using the Child-Pugh score, which predicts mortality based on parameters such as bilirubin levels, albumin levels, INR, ascites, and encephalopathy. The score ranges from A to C, with higher scores indicating a poorer prognosis.

Complications of cirrhosis include portal hypertension, ascites, hepatic encephalopathy, variceal hemorrhage, increased infection risk, hepatocellular carcinoma, and cardiovascular complications.

Diagnosis of cirrhosis is typically done through liver function tests, blood tests, viral hepatitis screening, and imaging techniques such as transient elastography or acoustic radiation force impulse imaging. Liver biopsy may also be performed in some cases.

Management of cirrhosis involves treating the underlying cause, controlling risk factors, and monitoring for complications. Complications such as ascites, spontaneous bacterial peritonitis, oesophageal varices, and hepatic encephalopathy require specific management strategies.

Overall, cirrhosis is a progressive condition that requires ongoing monitoring and management to prevent further complications and improve outcomes for patients.

In the UK, peptic ulcer disease is the leading cause of upper gastrointestinal bleeding. It surpasses all other listed causes combined in terms of prevalence.

Further Reading:

Upper gastrointestinal bleeding (UGIB) refers to the loss of blood from the gastrointestinal tract, occurring in the upper part of the digestive system. It can present as haematemesis (vomiting blood), coffee-ground emesis, bright red blood in the nasogastric tube, or melaena (black, tarry stools). UGIB can lead to significant hemodynamic compromise and is a major health burden, accounting for approximately 70,000 hospital admissions each year in the UK with a mortality rate of 10%.

The causes of UGIB vary, with peptic ulcer disease being the most common cause, followed by gastritis/erosions, esophagitis, and other less common causes such as varices, Mallory Weiss tears, and malignancy. Swift assessment, hemodynamic resuscitation, and appropriate interventions are essential for the management of UGIB.

Assessment of patients with UGIB should follow an ABCDE approach, and scoring systems such as the Glasgow-Blatchford bleeding score (GBS) and the Rockall score are recommended to risk stratify patients and determine the urgency of endoscopy. Transfusion may be necessary for patients with massive hemorrhage, and platelet transfusion, fresh frozen plasma (FFP), and prothrombin complex concentrate may be offered based on specific criteria.

Endoscopy plays a crucial role in the management of UGIB. Unstable patients with severe acute UGIB should undergo endoscopy immediately after resuscitation, while all other patients should undergo endoscopy within 24 hours of admission. Endoscopic treatment of non-variceal bleeding may involve mechanical methods of hemostasis, thermal coagulation, or the use of fibrin or thrombin with adrenaline. Proton pump inhibitors should only be used after endoscopy.

Variceal bleeding requires specific management, including the use of terlipressin and prophylactic antibiotics. Oesophageal varices can be treated with band ligation or transjugular intrahepatic portosystemic shunts (TIPS), while gastric varices may be treated with endoscopic injection of N-butyl-2-cyanoacrylate or TIPS if bleeding is not controlled.

For patients taking NSAIDs, aspirin, or clopidogrel, low-dose aspirin can be continued once hemostasis is achieved, NSAIDs should be stopped in patients presenting with UGIB.

One commonly used risk assessment tool for acute upper gastrointestinal bleeding is the Glasgow-Blatchford score. This score takes into account various factors such as blood pressure, heart rate, blood urea nitrogen levels, hemoglobin levels, and the presence of melena or syncope. By assigning points to each of these factors, the Glasgow-Blatchford score helps to stratify patients into low or high-risk categories.

Further Reading:

Upper gastrointestinal bleeding (UGIB) refers to the loss of blood from the gastrointestinal tract, occurring in the upper part of the digestive system. It can present as haematemesis (vomiting blood), coffee-ground emesis, bright red blood in the nasogastric tube, or melaena (black, tarry stools). UGIB can lead to significant hemodynamic compromise and is a major health burden, accounting for approximately 70,000 hospital admissions each year in the UK with a mortality rate of 10%.

The causes of UGIB vary, with peptic ulcer disease being the most common cause, followed by gastritis/erosions, esophagitis, and other less common causes such as varices, Mallory Weiss tears, and malignancy. Swift assessment, hemodynamic resuscitation, and appropriate interventions are essential for the management of UGIB.

Assessment of patients with UGIB should follow an ABCDE approach, and scoring systems such as the Glasgow-Blatchford bleeding score (GBS) and the Rockall score are recommended to risk stratify patients and determine the urgency of endoscopy. Transfusion may be necessary for patients with massive hemorrhage, and platelet transfusion, fresh frozen plasma (FFP), and prothrombin complex concentrate may be offered based on specific criteria.

Endoscopy plays a crucial role in the management of UGIB. Unstable patients with severe acute UGIB should undergo endoscopy immediately after resuscitation, while all other patients should undergo endoscopy within 24 hours of admission. Endoscopic treatment of non-variceal bleeding may involve mechanical methods of hemostasis, thermal coagulation, or the use of fibrin or thrombin with adrenaline. Proton pump inhibitors should only be used after endoscopy.

Variceal bleeding requires specific management, including the use of terlipressin and prophylactic antibiotics. Oesophageal varices can be treated with band ligation or transjugular intrahepatic portosystemic shunts (TIPS), while gastric varices may be treated with endoscopic injection of N-butyl-2-cyanoacrylate or TIPS if bleeding is not controlled.

For patients taking NSAIDs, aspirin, or clopidogrel, low-dose aspirin can be continued once hemostasis is achieved, NSAIDs should be stopped in patients presenting with UGIB

If a child with gastroenteritis shows signs of jittery movements, increased muscle tone, hyper-reflexia, or convulsions, hypernatraemic dehydration should be considered. Additional signs of hypernatraemic dehydration include drowsiness or coma.

Further Reading:

Gastroenteritis is a common condition in children, particularly those under the age of 5. It is characterized by the sudden onset of diarrhea, with or without vomiting. The most common cause of gastroenteritis in infants and young children is rotavirus, although other viruses, bacteria, and parasites can also be responsible. Prior to the introduction of the rotavirus vaccine in 2013, rotavirus was the leading cause of gastroenteritis in children under 5 in the UK. However, the vaccine has led to a significant decrease in cases, with a drop of over 70% in subsequent years.

Norovirus is the most common cause of gastroenteritis in adults, but it also accounts for a significant number of cases in children. In England & Wales, there are approximately 8,000 cases of norovirus each year, with 15-20% of these cases occurring in children under 9.

When assessing a child with gastroenteritis, it is important to consider whether there may be another more serious underlying cause for their symptoms. Dehydration assessment is also crucial, as some children may require intravenous fluids. The NICE traffic light system can be used to identify the risk of serious illness in children under 5.

In terms of investigations, stool microbiological testing may be indicated in certain cases, such as when the patient has been abroad, if diarrhea lasts for more than 7 days, or if there is uncertainty over the diagnosis. U&Es may be necessary if intravenous fluid therapy is required or if there are symptoms and/or signs suggestive of hypernatremia. Blood cultures may be indicated if sepsis is suspected or if antibiotic therapy is planned.

Fluid management is a key aspect of treating children with gastroenteritis. In children without clinical dehydration, normal oral fluid intake should be encouraged, and oral rehydration solution (ORS) supplements may be considered. For children with dehydration, ORS solution is the preferred method of rehydration, unless intravenous fluid therapy is necessary. Intravenous fluids may be required for children with shock or those who are unable to tolerate ORS solution.

Antibiotics are generally not required for gastroenteritis in children, as most cases are viral or self-limiting. However, there are some exceptions, such as suspected or confirmed sepsis, Extraintestinal spread of bacterial infection, or specific infections like Clostridium difficile-associated pseudomembranous enterocolitis or giardiasis.

Clostridium difficile is a type of bacteria that is Gram-positive, anaerobic, and capable of forming spores. When individuals take broad-spectrum antibiotics, it can disrupt the normal bacteria in the bowel and allow C. difficile to multiply. This can lead to inflammation and bleeding in the mucosa of the large intestine, resulting in a distinct appearance known as pseudomembranous. The main symptoms of C. difficile infection (CDI) include abdominal cramps, bloody and/or watery diarrhea, and fever. It is worth noting that the majority of CDI cases occur in individuals over the age of 65.

CDI is considered to be the most severe consequence of antibiotic treatment and is now a significant cause of illness and death. While CDI can occur after treatment with any antibiotic, the risk is particularly high with prolonged use of broad-spectrum antibiotics. Recently, two research groups conducted a meta-analysis to assess the risk associated with different classes of antibiotics.

Their findings revealed that the risk of CDI increased nearly sevenfold after antibiotic treatment (odds ratio, 6.91). Among the various antibiotic classes, clindamycin posed the greatest risk (odds ratio, 20.43), followed by fluoroquinolones (odds ratio, 5.65), cephalosporins (odds ratio, 4.47), penicillins (odds ratio, 3.25), macrolides (odds ratio, 2.55), and trimethoprim/sulfonamides (odds ratio, 1.84). Tetracyclines, on the other hand, were not found to be associated with an increased risk of CDI (odds ratio, 0.91).

For more information on this topic, you may consider reading the article Antibiotic Classes and Risk for Clostridium difficile Infection.

Spontaneous bacterial peritonitis (SBP) is a sudden bacterial infection of the fluid in the abdomen. It typically occurs in patients with high blood pressure in the portal vein, and about 70% of cases are seen in patients with severe liver disease. In any given year, around 30% of patients with fluid buildup in the abdomen will develop SBP.

SBP can present with a wide range of symptoms, so it’s important to be vigilant when caring for patients with fluid buildup in the abdomen, especially if there is a sudden decline in their condition. Some patients may not show any symptoms at all.

Common clinical features of SBP include fever (80% of cases), abdominal pain (70% of cases), worsening or unexplained confusion due to liver dysfunction, diarrhea, nausea and vomiting, and bowel obstruction.

There are several factors that increase the risk of developing SBP, including severe liver disease (Child-Pugh class C), gastrointestinal bleeding, urinary tract infection, excessive growth of bacteria in the intestines, presence of indwelling lines such as central venous catheters or urinary catheters, previous episodes of SBP, and low levels of protein in the fluid buildup in the abdomen.

To diagnose SBP, a procedure called abdominal paracentesis is performed to collect fluid from the abdomen. The following findings on fluid analysis strongly suggest SBP: total white blood cell count in the fluid greater than 500 cells/µL, total neutrophil count in the fluid greater than 250 cells/µL, lactate level in the fluid higher than 25 mg/dL, pH of the fluid below 7.35, and presence of bacteria on Gram-stain.

Patients with SBP should be admitted to the hospital and treated with broad-spectrum antibiotics. The preferred antibiotic is an intravenous third-generation cephalosporin, such as Ceftriaxone. If the patient is allergic to beta-lactam antibiotics, ciprofloxacin can be considered as an alternative. Administration of intravenous albumin has been shown to reduce the risk of kidney failure and death.

In this scenario, a 35-year-old female presents to the emergency department with complaints of abdominal cramps and bloating. She mentions that she has not had a bowel movement for 2 days. After conducting blood tests, which all come back normal, and assessing her vital signs, which are also normal, it is suspected that she may have constipation predominant irritable bowel syndrome. This suspicion is based on her history of recurrent abdominal pain and bloating over the past 6-9 months, for which she has already consulted her primary care physician.

To address the constipation symptoms, a laxative is considered as a potential treatment option. However, it is important to exercise caution when prescribing medications for patients with irritable bowel syndrome. One medication that should be avoided in these patients is lactulose.

Further Reading:

Irritable bowel syndrome (IBS) is a chronic disorder that affects the interaction between the gut and the brain. The exact cause of IBS is not fully understood, but factors such as genetics, drug use, enteric infections, diet, and psychosocial factors are believed to play a role. The main symptoms of IBS include abdominal pain, changes in stool form and/or frequency, and bloating. IBS can be classified into subtypes based on the predominant stool type, including diarrhea-predominant, constipation-predominant, mixed, and unclassified.

Diagnosing IBS involves using the Rome IV criteria, which includes recurrent abdominal pain associated with changes in stool frequency and form. It is important to rule out other more serious conditions that may mimic IBS through a thorough history, physical examination, and appropriate investigations. Treatment for IBS primarily involves diet and lifestyle modifications. Patients are advised to eat regular meals with a healthy, balanced diet and adjust their fiber intake based on symptoms. A low FODMAP diet may be trialed, and a dietician may be consulted for guidance. Regular physical activity and weight management are also recommended.

Psychosocial factors, such as stress, anxiety, and depression, should be addressed and managed appropriately. If constipation is a predominant symptom, soluble fiber supplements or foods high in soluble fiber may be recommended. Laxatives can be considered if constipation persists, and linaclotide may be tried if optimal doses of previous laxatives have not been effective. Antimotility drugs like loperamide can be used for diarrhea, and antispasmodic drugs or low-dose tricyclic antidepressants may be prescribed for abdominal pain. If symptoms persist or are refractory to treatment, alternative diagnoses should be considered, and referral to a specialist may be necessary.

Overall, the management of IBS should be individualized based on the patient’s symptoms and psychosocial situation. Clear explanation of the condition and providing resources for patient education, such as the NHS patient information leaflet and support from organizations like The IBS Network, can also be beneficial.